Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pan Ji

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Bioorganic & Medicinal Chemistry Letters|July 15, 2011
Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domainXiao-Fei Zeng, Wei-Wei Li, Hui-Jin Fan, et al.
Plos One|December 24, 2011
Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancersJian-Ping Zhou, Xin Chen, Shan Feng, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|July 23, 2013
SC-535, a novel oral multikinase inhibitor, showed potent antitumor activity in human melanoma modelsXin Chen, Pan Ji, Hui-Wen Yang, et al.
Organic Letters|January 26, 2017
IgG Antibody Response Elicited by a Fully Synthetic Two-Component Carbohydrate-Based Cancer Vaccine Candidate with α-Galactosylceramide as Built-in AdjuvantXu-Guang Yin, Xiang-Zhao Chen, Wen-Mei Sun, et al.
Journal of Medicinal Chemistry|November 3, 2012
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutationsJiao Yang, Li-Jiao Wang, Jing-Jing Liu, et al.
Molecular Cancer Therapeutics|February 10, 2012
SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivoYouli Pan, Yong Xu, Shan Feng, et al.
Thoracic Cancer|November 7, 2019
Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patientsYing Ding, Lihua Zhang, Lingchuan Guo, et al.
Journal of Medicinal Chemistry|March 29, 2012
Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivoWei-Wei Li, Xiao-Yan Wang, Ren-Lin Zheng, et al.
Nature|February 4, 2026
Synthesizing scientific literature with retrieval-augmented language modelsAkari Asai, Jacqueline He, Rulin Shao, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Bioorganic & Medicinal Chemistry Letters|July 15, 2011
Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domainXiao-Fei Zeng, Wei-Wei Li, Hui-Jin Fan, et al.
Plos One|December 24, 2011
Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancersJian-Ping Zhou, Xin Chen, Shan Feng, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|July 23, 2013
SC-535, a novel oral multikinase inhibitor, showed potent antitumor activity in human melanoma modelsXin Chen, Pan Ji, Hui-Wen Yang, et al.
Organic Letters|January 26, 2017
IgG Antibody Response Elicited by a Fully Synthetic Two-Component Carbohydrate-Based Cancer Vaccine Candidate with α-Galactosylceramide as Built-in AdjuvantXu-Guang Yin, Xiang-Zhao Chen, Wen-Mei Sun, et al.
Journal of Medicinal Chemistry|November 3, 2012
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutationsJiao Yang, Li-Jiao Wang, Jing-Jing Liu, et al.
Molecular Cancer Therapeutics|February 10, 2012
SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivoYouli Pan, Yong Xu, Shan Feng, et al.
Thoracic Cancer|November 7, 2019
Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patientsYing Ding, Lihua Zhang, Lingchuan Guo, et al.
Journal of Medicinal Chemistry|March 29, 2012
Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivoWei-Wei Li, Xiao-Yan Wang, Ren-Lin Zheng, et al.
Nature|February 4, 2026
Synthesizing scientific literature with retrieval-augmented language modelsAkari Asai, Jacqueline He, Rulin Shao, et al.
Pageof 6